Mechanism-Targeted Receptor Pharmacotherapy
Small molecules and peptides designed against a specific receptor or deficient signalling pathway treat the underlying biological cause of neurological and cardiometabolic disease rather than its symptoms.
Developed mainly in: United StatesImpacting: North America and Europe
The FDA approved Eli Lilly's tirzepatide (Mounjaro) for reducing major adverse cardiovascular events — including heart attack, stroke, and CV death — in type 2 diabetes adults at high cardiovascular risk. The dual GIP/GLP-1 receptor agonist becomes the first in its class to carry this specific CV indication, extending beyond its existing blood sugar and weight loss approvals.
This is one of 24 signals scored in our latest scan.
Track Them Free For 14 Days →Since we flagged this
First flagged
7 August 2026 · score 7.0/10
Corroborating sources since flagging
56
Latest signals
Tracked from 3 signals, each traced to its source.
- FDA Grants Mounjaro Cardiovascular Risk Reduction Approval for Type 2 Diabetes Adults
Prnewswire · 28 Aug 2026
- FDA Approves First Orexin Receptor Agonist Targeting Root Cause of Narcolepsy Type 1
Biospace · 26 Aug 2026
- FDA Approves Centanafadine as First NDSRI Mechanism ADHD Treatment
Otsuka · 7 Aug 2026
In the full record
Evolution
Score over time, Score Jumps and how the evidence built up since the first signal.
Thesis
Paradigm Shift, Commercial Viability, signal strength and the driver of the change.
Why this innovation matters
The full analysis: what is shifting, who is affected and the second-order effects.
Forecasted Hypothesis
What would strengthen this innovation, and what would weaken it.
Exposure
Companies and publicly listed stock symbols linked to this innovation.
Every signal
Each signal with its date, score, flags and original source.
Open the full record free for 14 days → No card needed.
More in Healthcare
Other innovations the engine is currently tracking in this industry.
- Image-Based Cancer Prognostic Modelling6.5/ 10 · 2 signals
- Hospital-At-Home Continuous Vital-Sign Patches5.0/ 10 · 2 signals
- Automated Quantitative Imaging Biomarkers5.5/ 10 · 2 signals
- Prescription Digital Therapeutics7.0/ 10 · 10 signals
- Oral Small-Molecule GLP-1 Agonists7.8/ 10 · 6 signals
- At-Home Prescription Neuromodulation6.5/ 10 · 2 signals
Track every innovation, free for 14 days
Full Analyst access from the first day. No card. Then subscribe to keep it.
- The radar: every innovation, ranked by Disruption Score
- Tracked evolution: score over time, Score Jumps and how the evidence built up
- Thesis and analysis: Commercial Viability, Paradigm Shift, why it matters, what would change it
- Geography: where each innovation is developed and where it has impact
- Exposure: the companies and public stock symbols behind each innovation
- Every signal with its source, and what moved since your last visit
- Email alerts when an innovation moves: First Signal, Score Jump and briefings
Disclaimer: The information provided on this page is for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Stock data shown is illustrative and may not reflect real-time prices. Always conduct your own research and consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.